Wockhardt Advised By U.S. FDA To Reassess Entire Drug-Making Process
This article was originally published in PharmAsia News
Executive Summary
The U.S. FDA has raised questions about the integrity of all data Wockhardt generated in support of its drugs for export and advised it to review its entire manufacturing process, not just the three plants already cited.